WO2000014537A3 - Immunoconjugate for diagnosis of multidrug resistance - Google Patents

Immunoconjugate for diagnosis of multidrug resistance Download PDF

Info

Publication number
WO2000014537A3
WO2000014537A3 PCT/US1999/020017 US9920017W WO0014537A3 WO 2000014537 A3 WO2000014537 A3 WO 2000014537A3 US 9920017 W US9920017 W US 9920017W WO 0014537 A3 WO0014537 A3 WO 0014537A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoconjugate
diagnosis
multidrug resistant
multidrug
multidrug resistance
Prior art date
Application number
PCT/US1999/020017
Other languages
French (fr)
Other versions
WO2000014537A2 (en
Inventor
David M Goldenberg
Original Assignee
Immunomedics Inc
David M Goldenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, David M Goldenberg filed Critical Immunomedics Inc
Priority to AU57991/99A priority Critical patent/AU5799199A/en
Publication of WO2000014537A2 publication Critical patent/WO2000014537A2/en
Publication of WO2000014537A3 publication Critical patent/WO2000014537A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Immunoconjugates of a diagnostic agent and an antibody component that binds an epitope of a multidrug transporter protein are disclosed. Thesse immunoconjugates are used in in vivo diagnostic methods to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.
PCT/US1999/020017 1998-09-04 1999-09-01 Immunoconjugate for diagnosis of multidrug resistance WO2000014537A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57991/99A AU5799199A (en) 1998-09-04 1999-09-01 Diagnosis of multidrug resistance in cancer and infectious lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9930498P 1998-09-04 1998-09-04
US60/099,304 1998-09-04

Publications (2)

Publication Number Publication Date
WO2000014537A2 WO2000014537A2 (en) 2000-03-16
WO2000014537A3 true WO2000014537A3 (en) 2000-07-20

Family

ID=22274363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020017 WO2000014537A2 (en) 1998-09-04 1999-09-01 Immunoconjugate for diagnosis of multidrug resistance

Country Status (2)

Country Link
AU (1) AU5799199A (en)
WO (1) WO2000014537A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240772B1 (en) * 2018-06-11 2022-06-06 Nanothea Spolka Akcyjna Method of producing polymer nanoparticles chelating radioactive isotopes for use in diagnostics and treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008802A1 (en) * 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1993002105A1 (en) * 1991-07-19 1993-02-04 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
WO1993019094A1 (en) * 1992-03-20 1993-09-30 Board Of Trustees Of The University Of Illinois A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses
WO1993025700A1 (en) * 1992-06-17 1993-12-23 Istituto Superiore Di Sanita' Monoclonal antibodies to glycoprotein p
WO1996004313A1 (en) * 1994-08-05 1996-02-15 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008802A1 (en) * 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1993002105A1 (en) * 1991-07-19 1993-02-04 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
WO1993019094A1 (en) * 1992-03-20 1993-09-30 Board Of Trustees Of The University Of Illinois A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses
WO1993025700A1 (en) * 1992-06-17 1993-12-23 Istituto Superiore Di Sanita' Monoclonal antibodies to glycoprotein p
WO1996004313A1 (en) * 1994-08-05 1996-02-15 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARTNER N. ET AL: "Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies", NATURE, vol. 316, no. 29, August 1985 (1985-08-01), pages 820 - 823, XP000857277 *

Also Published As

Publication number Publication date
AU5799199A (en) 2000-03-27
WO2000014537A2 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
CA2195556A1 (en) Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1999058570A3 (en) Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
EP1808155A3 (en) Antibody-serum protein hybrids
NO984136D0 (en) Humanized chimeric antibody molecule for use as a dianostic, and diagnostic composition comprising such an antibody molecule
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
EP0753072A1 (en) Biological markers of benign prostate hyperplasia
HUP9702359A3 (en) Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO1999065947A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
TR200102877T2 (en) Anti-idiotypic antibodies against antibodies that inhibit the binding of immunoglobulin to its own high affinity receptor.
WO1992002819A3 (en) Assay for ulcerative colitis and primary sclerosing cholangitis
WO2000014537A3 (en) Immunoconjugate for diagnosis of multidrug resistance
EP0453097A3 (en) Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
WO2002050546A3 (en) Method and use of the cytosolic nadp-dependent malate-decarboxylase isoenzyme for identifying a malignant process, and a suitable test kit
CA2102115A1 (en) In vitro methods for determining in vivo thrombotic events
ZA9710391B (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent.
AR243932A1 (en) Hybridomas, procedure for their preparation, monoclonal antibodies, the procedure for their preparation and a compound for diagnosis based on the antibody.
CA2088889A1 (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
WO2000017658A3 (en) Diagnosis of myocardial disease or stroke using factor ix activation peptide
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
WO2000009076A3 (en) Imaging with tc-99m labeled fibrin-alpha-chain peptide
WO1999002564A3 (en) Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase